Sunnyou Medical announced on April 19 that Suzhou Jifeng Equity Investment Partnership (L.P.), Jiaxing Jifeng I Equity Investment Partnership (L.P.), and Fuzhou Jifeng Equity Investment Partnership (L.P.), acting as concert parties, plan to reduce their shares in the company by no more than 8.4001 million shares through centralized bidding or block trading due to their own capital needs. The total reduction ratio will not exceed 5.25% of the company's total share capital. This reduction plan will be implemented within six months (from May 16, 2023, to November 15, 2023) after 15 trading days from the date of this announcement.
Among them, Suzhou Jifeng Equity Investment Partnership (L.P.) plans to reduce no more than 4.8007 million company shares, with a reduction ratio not exceeding 3.00%; Jiaxing Jifeng I Equity Investment Partnership (L.P.) plans to reduce no more than 2.7031 million company shares, with a reduction ratio not exceeding 1.69%; Fuzhou Jifeng Equity Investment Partnership (L.P.) plans to reduce 896,200 shares, with a reduction ratio not exceeding 0.56%.
As of the date of this announcement, Suzhou Jifeng Equity Investment Partnership (L.P.) holds 4.8007 million shares of the company, accounting for 3.00% of the total share capital; Jiaxing Jifeng I Equity Investment Partnership (L.P.) holds 2.7031 million shares, accounting for 1.69% of the total share capital; Fuzhou Jifeng Equity Investment Partnership (L.P.) holds 0.8962 million shares, accounting for 0.56% of the total share capital.
Suzhou Jifeng, Jiaxing Jifeng I, and Fuzhou Jifeng collectively hold 8.4001 million shares of the company, accounting for 5.25% of the company's total share capital.